We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher Stock Benefits From the Launch of Krios 5 Cryo-TEM
Read MoreHide Full Article
Thermo Fisher Scientific (TMO - Free Report) has unveiled its latest customer-centric innovation, the Thermo Scientific Krios 5 Cryo-Transmission Electron Microscope (TEM). The next-generation atomic-resolution platform uses enhanced optics and AI-enabled automation to study molecular structures and interactions at throughput and fidelity that was previously out of reach.
The development is expected to bolster the company’s Materials and Structural Analysis business unit.
TMO Stock’s Likely Trend Following the News
After the announcement on April 2, Thermo Fisher’s shares inched up 1.3%, finishing the session at $489.06. The new Krios 5 Cryo-TEM reflects the company’s focus on customer-driven innovations. By providing unmatched automation and throughput, it enables researchers and the pharmaceutical industry to uncover new insights and fight diseases better than ever before. Hence, we expect the latest news to positively influence the market sentiment for TMO stock.
Presently, Thermo Fisher boasts a market capitalization of $184.50 billion. The company’s earnings yield of 4.8% is well ahead of the industry’s -3.5% yield. It surpassed earnings estimates in each of the trailing four quarters, delivering an earnings surprise of 4.2%.
More on Thermo Fisher’s New Tech Collaboration
Single particle analysis (SPA) and cryo-electron tomography (cryo-ET) are powerful techniques in the rapidly evolving field of structural biology, allowing scientists to better understand the intricacies of biology and providing atomic-level insights that reveal how viruses, proteins and cells work. The Krios 5 Cryo-TEM optimizes productivity and performance to boost these techniques.
Image Source: Zacks Investment Research
With a throughput improvement of up to 25% compared with previously released models, the Krios 5 enables 3D visualization of proteins, as well as their interactions and dynamics within the biological cell. Other Krios 5 advantages include AI-powered experimental set-up and upgraded data acquisition. For the cryo-ET workflow, the innovative vacuum capsule transfer helps prevent contamination of samples. Collectively, these enhancements build on Thermo Fisher’s cryo-EM legacy with a new generation of Krios that will enable researchers to pioneer new treatments and advance drug discovery.
Furthermore, the Krios 5 has a low-power stand-by mode with rapid wake-up capabilities, minimizing energy consumption while not in use without delaying experiments. Certified with the My Green Lab ACT Ecolabel, the Krios 5 supports the sustainability goals of customers and the scientific community.
Thermo Fisher’s Industry Prospects
A research report estimates that the global cryo-EM market will reach $1.45 billion in 2025 and witness a compound annual rate of 11.9% through 2032. A key driver of the market’s growth in recent years has been the increasing focus on structural biology projects worldwide. Rising funding for cryo-EM from government and private organizations and technological advancements play a role.
More Updates From Thermo Fisher
Last month, the company unveiled new lines of floor-model centrifuges to offer more sustainable solutions without compromising performance and sample security. The Thermo Scientific Cryofuge, Thermo Scientific BIOS and Thermo Scientific LYNX centrifuges are the first floor-model centrifuges that feature natural refrigerant cooling systems compliant with European Union (E.U.) and U.S. Environmental Protection Agency (EPA) F-gas regulations.
TMO Stock Price Performance
In the past six months, TMO shares have lost 21.5% compared with the industry’s 7.5% decline.
TMO’s Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Estimates for Hims & Hers Health’s 2025 earnings per share have remained constant at 63 cents in the past 30 days. Shares of the company have surged 92.9% in the past year against the industry’s 1.3% fall. Its earnings yield of 2% also outpaced the industry’s -7.4% yield. HIMS’ earnings surpassed estimates in two of the trailing four quarters, matched in one and missed on another occasion, the average surprise being 40.4%.
Boston Scientific shares have rallied 43.6% in the past year. Estimates for the company’s 2025 earnings per share have remained constant at $2.85 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 8.3%. In the last reported quarter, it posted an earnings surprise of 7.7%.
Estimates for Abbott’s 2025 earnings per share have remained constant at $5.15 in the past 30 days. Shares of the company have jumped 18.4% in the past year compared to the industry’s 10.3% growth. Its earnings yield of 3.9% compares to the industry’s flat yield. ABT’searnings surpassed estimates in three of the trailing four quarters and matched in one, the average surprise being 1.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Thermo Fisher Stock Benefits From the Launch of Krios 5 Cryo-TEM
Thermo Fisher Scientific (TMO - Free Report) has unveiled its latest customer-centric innovation, the Thermo Scientific Krios 5 Cryo-Transmission Electron Microscope (TEM). The next-generation atomic-resolution platform uses enhanced optics and AI-enabled automation to study molecular structures and interactions at throughput and fidelity that was previously out of reach.
The development is expected to bolster the company’s Materials and Structural Analysis business unit.
TMO Stock’s Likely Trend Following the News
After the announcement on April 2, Thermo Fisher’s shares inched up 1.3%, finishing the session at $489.06. The new Krios 5 Cryo-TEM reflects the company’s focus on customer-driven innovations. By providing unmatched automation and throughput, it enables researchers and the pharmaceutical industry to uncover new insights and fight diseases better than ever before. Hence, we expect the latest news to positively influence the market sentiment for TMO stock.
Presently, Thermo Fisher boasts a market capitalization of $184.50 billion. The company’s earnings yield of 4.8% is well ahead of the industry’s -3.5% yield. It surpassed earnings estimates in each of the trailing four quarters, delivering an earnings surprise of 4.2%.
More on Thermo Fisher’s New Tech Collaboration
Single particle analysis (SPA) and cryo-electron tomography (cryo-ET) are powerful techniques in the rapidly evolving field of structural biology, allowing scientists to better understand the intricacies of biology and providing atomic-level insights that reveal how viruses, proteins and cells work. The Krios 5 Cryo-TEM optimizes productivity and performance to boost these techniques.
Image Source: Zacks Investment Research
With a throughput improvement of up to 25% compared with previously released models, the Krios 5 enables 3D visualization of proteins, as well as their interactions and dynamics within the biological cell. Other Krios 5 advantages include AI-powered experimental set-up and upgraded data acquisition. For the cryo-ET workflow, the innovative vacuum capsule transfer helps prevent contamination of samples. Collectively, these enhancements build on Thermo Fisher’s cryo-EM legacy with a new generation of Krios that will enable researchers to pioneer new treatments and advance drug discovery.
Furthermore, the Krios 5 has a low-power stand-by mode with rapid wake-up capabilities, minimizing energy consumption while not in use without delaying experiments. Certified with the My Green Lab ACT Ecolabel, the Krios 5 supports the sustainability goals of customers and the scientific community.
Thermo Fisher’s Industry Prospects
A research report estimates that the global cryo-EM market will reach $1.45 billion in 2025 and witness a compound annual rate of 11.9% through 2032. A key driver of the market’s growth in recent years has been the increasing focus on structural biology projects worldwide. Rising funding for cryo-EM from government and private organizations and technological advancements play a role.
More Updates From Thermo Fisher
Last month, the company unveiled new lines of floor-model centrifuges to offer more sustainable solutions without compromising performance and sample security. The Thermo Scientific Cryofuge, Thermo Scientific BIOS and Thermo Scientific LYNX centrifuges are the first floor-model centrifuges that feature natural refrigerant cooling systems compliant with European Union (E.U.) and U.S. Environmental Protection Agency (EPA) F-gas regulations.
TMO Stock Price Performance
In the past six months, TMO shares have lost 21.5% compared with the industry’s 7.5% decline.
TMO’s Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space include Hims & Hers Health (HIMS - Free Report) , Boston Scientific (BSX - Free Report) and Abbott (ABT - Free Report) . Each of these carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Estimates for Hims & Hers Health’s 2025 earnings per share have remained constant at 63 cents in the past 30 days. Shares of the company have surged 92.9% in the past year against the industry’s 1.3% fall. Its earnings yield of 2% also outpaced the industry’s -7.4% yield. HIMS’ earnings surpassed estimates in two of the trailing four quarters, matched in one and missed on another occasion, the average surprise being 40.4%.
Boston Scientific shares have rallied 43.6% in the past year. Estimates for the company’s 2025 earnings per share have remained constant at $2.85 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 8.3%. In the last reported quarter, it posted an earnings surprise of 7.7%.
Estimates for Abbott’s 2025 earnings per share have remained constant at $5.15 in the past 30 days. Shares of the company have jumped 18.4% in the past year compared to the industry’s 10.3% growth. Its earnings yield of 3.9% compares to the industry’s flat yield. ABT’searnings surpassed estimates in three of the trailing four quarters and matched in one, the average surprise being 1.6%.